Lytix takes lead antimicrobial compound into clinic
The Scandinavian drug development company Lytix Biopharma has announced plans to take its lead ultra-broad spectrum antimicrobial through to clinical trials.
The Scandinavian drug development company Lytix Biopharma has announced plans to take its lead ultra-broad spectrum antimicrobial through to clinical trials.
Broadly effective through rapid and selective cell lysis against highly resistant bacterial strains such as MRSA, the novel class of small molecules exhibits an extremely low propensity for resistance development, the company said.
According to Lytix ceo Øystein Rekdal, extensive preclinical studies have documented excellent efficacy for topical treatment: "Animal skin infection studies showed outstanding efficacy against Gram positive bacteria. Indeed, complete eradication of the test organism was obtained within 24 hours."
Toxicology and formulation work is already underway and we expect to able to submit our IND in the beginning of 2009. We have now chosen to partner with SAFC Pharma for the production of our lead compound in support of clinical trials."
